top of page
ade (3).png

FOR DRUG DEVELOPMENT

HIGH-PURITY IBOGAINE HCl AND ITS KEY PRECURSOR, VOACANGINE

Reliable, scalable supply for R&D and clinical-stage programs.

Sustainable sourced from the Amazon rainforest.
GMP-compliant. Global supply.

FOR DRUG DEVELOPMENT

About us

Hylaea is a Brazilian biotech company supplying voacangine as a strategic semisynthetic precursor for ibogaine and next-generation derivatives.

In parallel, we are developing the production of ibogaine hydrochloride, advancing toward a fully integrated supply of ibogaine-based compounds.

Our Products

Voacangine ready for your pipeline

High-purity voacangine suitable for the semi-synthesis of ibogaine and next-generation therapeutics, supported by validated production and proven use in international biotech programs.
 

  • High purity and batch consistency
     

  • Scalable production
     

  • Sustainable sourcing

1.png

Ibogaine hydrochloride
(in development)

Innovative and proprietary semisynthetic route.
 

  • High yield and selectivity

​

  • High purity with controlled impurity profile

​

  • Scalable and robust process

​

  • Sustainable and cost-efficient production

2.png
2.png

Sustainability

The world’s largest tropical rainforest is our living laboratory

We combine sustainable practices and advanced tecnology to deliver high-quality, scalable compounds while preserving the Amazon's ecollogical balance.


  • Alternative natural sources of iboga alkaloids

  • Superior extraction yields compared to African species

  • Non-destructive harvesting

  • Local community engagement

Design sem nome (24).png
bottom of page